StockNews.AI
GRI
StockNews.AI
95 days

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

1. GRI Bio CEO Marc Hertz to speak at A.G.P.'s showcase on May 21. 2. The company focuses on NKT cell modulators for autoimmune diseases. 3. GRI-0621 targets iNKT cells for idiopathic pulmonary fibrosis treatment. 4. GRI Bio has over 500 proprietary compounds in its pipeline. 5. Potential market growth due to significant unmet medical needs.

4m saved
Insight
Article

FAQ

Why Bullish?

GRI's presentation at a healthcare showcase can boost investor interest, potentially increasing stock demand. Similar events in the past have positively influenced biotech stock prices due to enhanced visibility.

How important is it?

The showcase could increase GRI's exposure, yet depends on the reception of their pipeline. Increased visibility can lead to investor confidence and future partnerships.

Why Short Term?

Immediate market reactions are expected following the showcase, with potential for volatility. Historical data shows spikes in stock performance after investor engagements.

Related Companies

NKREGNBMY
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21, 2025 at 2:40 PM ET. Click here to register for the event. A live webcast of the fireside chat will be accessible on the Events page under the Investors section of the Company’s website (gribio.com). About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775GRI@jtcir.com

Related News